Cellectis S.A. - CLLS Income before deduction of interest, taxes and amortization

Graphic logo of Cellectis (CLLS)

Stable licensing revenue from Cellectis S.A. (CLLS) supports the balance sheet, as confirmed by the EBITDA cash flow; meanwhile, the value of 0.00 characterizes this level. Geopolitical fragmentation and logistical disruptions between the US and Europe are hindering global trials. However, a strategic alliance with a pharma behemoth is accelerating the launch of allogeneic CAR-T therapies through external funding.

CLLS Cellectis Operating profit EBITDA (11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for Cellectis (CLLS)

- market value and analyst target forecast:
Market Price Cellectis SA|CLLS - Consensus Target
- issuer market value details:
Market Value Cellectis S.A.|CLLS - Enterprise Value
- book capitalization information:
Accounting Value per Share Cellectis S.A.|CLLS - Book Capitalization|Market-to-Book Ratio cellectis.com|CLLS - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Cellectis S.A.|CLLS - Long-Term Debt to Equity|Short-Term Debt to Equity Cellectis SA|CLLS - Company Total Debt|Debt to Net Assets Ratio Cellectis S.A.|CLLS - Company Long-Term Debts|Short-Term Indebtedness Cellectis S.A.|Immediate Liquidity cellectis.com
- earnings and multiples data:
CLLS - Company Net Income|Net Profit Forecast Cellectis S.A.|CLLS - P/E Multiple|Projected Price to Earnings Ratio Cellectis SA|CLLS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Cellectis S.A.|CLLS - Operating profit before deduction of amortization|Earnings per share for the last four quarters Cellectis S.A.|CLLS - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months cellectis.com|CLLS - Earnings growth in current year|Expected net earnings per share growth next year Cellectis S.A.
Fundamental company valuation:Cellectis S.A.
Manufactured products of Cellectis SA

Analyzing fundamental risks requires monitoring real cash flow from operating activities, which measures a business's ability to generate profit before depreciation and taxes. The operating earnings trend for Cellectis S.A. (CLLS) reflects the efficiency of monetizing CAR-T technology licenses, allowing investors to distinguish temporary market dips from a systemic decline in revenues from pharmaceutical partners and oncology centers.

Who Cellectis S.A. competes with

Legend Biotech Corp. (LEGN) - Profit before interest, taxes and amortization|SANA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AUTL (autolus.com)|ALLO: Operating profit EBITDA|Operating profit before deduction of amortization Selecta Biosciences|CRBU (Caribou Bio) - Operating profit EBITDA|Profit before interest, taxes and amortization Instil Bio Inc TIL|Profit before payment of interest, taxes and amortization Genenta Science S.p.A. (GNTA)|Profit before payment of interest, taxes and amortization IPSC (centurytx.com)|Profit before payment of interest, taxes and amortization Jasper Therapeutics, Inc. JSPR|Senti Bio - Profit before payment of interest, taxes and amortization|ADAP: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CERO (CERo Therapeutics)|TCRT: Operating profit EBITDA|Operating profit before depreciation charges Achilles Therapeutics plc ACHL|CRGX (CARGO Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Poseida Therapeutics Inc PSTX|Profit before payment of interest, taxes and amortization 2seventy Bio (TSVT)|Gracell - Operating profit before amortization